What is the recommended dosing, duration, and monitoring for amphotericin B (amphotericin B deoxycholate or liposomal formulation) in an adult with a serious systemic or invasive fungal infection?

Amphotericin B Dosing and Monitoring for Serious Systemic Fungal Infections

For serious invasive fungal infections in adults, amphotericin B deoxycholate should be dosed at 0.5-1.0 mg/kg/day (up to 1.5 mg/kg maximum) infused over 2-6 hours, while liposomal amphotericin B is dosed at 3-5 mg/kg/day, with treatment duration ranging from 2 weeks to several months depending on the specific infection and clinical response.

Formulation Selection

The choice between amphotericin B deoxycholate and liposomal formulations depends on infection severity, renal function, and tolerability:

• Amphotericin B deoxycholate remains effective but carries significant nephrotoxicity risk 1
• Liposomal amphotericin B (L-AmB) offers substantially reduced nephrotoxicity while maintaining equivalent efficacy 2, 3
• For CNS infections: L-AmB 5 mg/kg/day is strongly recommended as initial therapy 4
• For neonatal disseminated candidiasis: Amphotericin B deoxycholate 1 mg/kg/day is the preferred agent 4

Specific Dosing by Infection Type

Candidemia and Invasive Candidiasis

• Neonates: Amphotericin B deoxycholate 1 mg/kg/day (strong recommendation) 4
• Adults with CNS involvement: L-AmB 5 mg/kg/day initially, then step down to fluconazole 400-800 mg daily after response 4

Urinary Tract Candidiasis

• Cystitis (fluconazole-resistant): Amphotericin B deoxycholate 0.3-0.6 mg/kg/day for 1-7 days 4
• Pyelonephritis: Same dosing as cystitis 4
• Bladder irrigation: 50 mg/L sterile water daily for 5 days (for resistant species) 4

Ocular Candidiasis

• Chorioretinitis with macular involvement: L-AmB 3-5 mg/kg/day PLUS intravitreal amphotericin B deoxycholate 5-10 μg/0.1 mL 4
• Duration: Minimum 4-6 weeks based on ophthalmologic resolution 4

Aspergillosis and Invasive Molds

• Standard dose: L-AmB 3 mg/kg/day is as effective as higher doses 2
• High-dose strategy (10 mg/kg/day) showed no efficacy benefit and increased nephrotoxicity—not recommended 5
• Total cumulative dose: Up to 3.6 g for aspergillosis 1

Mucormycosis (Rhinocerebral Phycomycosis)

• Cumulative dose: Minimum 3 g total, with aggressive approach given rapid fatality 1
• Duration: Extended therapy until clinical and radiological resolution

Administration Protocol

Initial Test Dose

A 1 mg test dose in 20 mL 5% dextrose over 20-30 minutes is recommended, with vital signs monitored every 30 minutes for 2-4 hours 1

Dose Escalation for Amphotericin B Deoxycholate

• Good cardio-renal function: Start 0.25 mg/kg/day, escalate to 0.5-0.7 mg/kg/day 1
• Severe/rapidly progressive infection: May initiate at 0.3 mg/kg/day 1
• Impaired renal function: Start with 5-10 mg, increase by 5-10 mg/day as tolerated 1

Infusion Details

• Concentration: 0.1 mg/mL in 5% dextrose (pH >4.2) 1
• Rate: Infuse over 2-6 hours depending on dose 1
• Never exceed: 1.5 mg/kg/day total dose (risk of fatal cardiac arrest) 1

Critical Monitoring Parameters

Renal Function

• Baseline and frequent monitoring of serum creatinine is mandatory 1
• Risk factors for nephrotoxicity: Higher doses, longer duration, concomitant nephrotoxic drugs, pre-existing kidney disease 3
• Protective measures: IV saline hydration before and during therapy 3

Electrolytes

• Monitor closely: Potassium and magnesium levels 1
• Supplement proactively to prevent hypokalemia and hypomagnesemia 3
• Hypokalemia risk: Enhanced by corticosteroids and may potentiate digitalis toxicity 1

Additional Laboratory Tests

• Liver function tests
• Complete blood counts
• Hemoglobin concentrations 1

Infusion-Related Reactions

• Common: Fever, chills, hypotension, nausea, headache occurring 1-3 hours post-infusion 1
• More severe with initial doses, typically diminish with subsequent infusions 1
• L-AmB has significantly fewer infusion reactions than deoxycholate formulation 2, 6

Duration of Therapy

Treatment duration varies substantially by infection:

• Candidemia without metastatic complications: 2 weeks after blood culture clearance and symptom resolution 4
• CNS candidiasis: Until all signs, symptoms, CSF, and radiological abnormalities resolve 4
• Ocular involvement: Minimum 4-6 weeks with repeated ophthalmologic assessments 4
• Sporotrichosis: Up to 9 months (total dose up to 2.5 g) 1
• Aspergillosis: Up to 11 months (total dose up to 3.6 g) 1

Critical Pitfalls to Avoid

• Never use saline or bacteriostatic agents for reconstitution—causes precipitation 1
• Avoid rapid infusion—associated with hypotension, arrhythmias, and shock 1
• Separate leukocyte transfusions temporally from amphotericin B due to acute pulmonary toxicity risk 1
• Do not combine with other nephrotoxic agents (aminoglycosides, cyclosporine, pentamidine) without intensive renal monitoring 1
• If therapy interrupted >7 days, restart at lowest dose (0.25 mg/kg) and re-escalate 1

Source Control Considerations

Successful outcomes require addressing underlying factors:

• Remove central venous catheters in candidemia (strong recommendation) 4
• Remove urinary catheters when feasible 4
• Remove infected CNS devices (shunts, drains) if possible 4
• Surgical debridement for intra-abdominal candidiasis 4